Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A prognostic index for multiple myeloma

G Grignani1, P G Gobbi, R Formisano

  • 1Università di Pavia, IRCCS Policlinico S. Matteo, Italy.

British Journal of Cancer
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus.

Lupus·2019
Same author

Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study.

Clinical and experimental medicine·2019
Same author

Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review.

Lupus·2017
Same author

Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.

Cancer chemotherapy and pharmacology·2015
Same author

Identification of the hydration state in emergency patients: correlation between caval index and BUN/creatinine ratio.

European review for medical and pharmacological sciences·2013
Same author

DNA-ploidy and proliferative activity in uterine-tumors - an in-vivo study using bromodeoxyuridine and flow-cytometry.

Oncology reports·2011
Same journal

The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.

British journal of cancer·2026
Same journal

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same journal

Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.

British journal of cancer·2026
Same journal

Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.

British journal of cancer·2026
Same journal

De novo cancer-related mortality after solid organ transplantation in England: the EpCOT study.

British journal of cancer·2026
Same journal

Planetary Health Diet Index and breast cancer risk.

British journal of cancer·2026
See all related articles

This study introduces a new scoring system for multiple myeloma (MM) patients, improving prognosis prediction by combining diagnostic factors and treatment response. It helps identify patients needing aggressive therapy for better outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Current multiple myeloma (MM) prognostic systems inadequately identify patients requiring aggressive treatment.
  • Existing staging systems lack the reliability to differentiate prognoses effectively.

Purpose of the Study:

  • To enhance prognostic forecasting in MM by integrating clinical characteristics at diagnosis with first-line chemotherapy response.
  • To develop a more accurate model for predicting overall survival in MM patients.

Main Methods:

  • A prospective multicentre trial involving 231 patients randomized to different treatment arms.
  • Univariate and multivariate analyses were used to evaluate prognostic variables for overall survival.
  • A scoring system was developed incorporating statistically significant variables.

Related Experiment Videos

Main Results:

  • Three key variables demonstrated statistical significance: British Medical Research Council staging, a composite parameter of bone marrow plasma cells and cytological features, and response to 6-month chemotherapy.
  • The developed scoring system identified three distinct risk classes with significantly different median overall survival (52, 28, and 13 months).

Conclusions:

  • The proposed scoring system, utilizing diagnostic and therapeutic parameters, offers a flexible tool for individual MM patient prognosis.
  • This system can aid in stratifying MM patients into comparable groups, guiding therapy selection, and evaluating treatment response.